BioProtect
Biodegradable Balloons for Safe Radiation Therapy
Company Overview
Snapshot
Founded in September 2004 by Shaul Shohat, BioProtect operates with 51–200 employees. The company has raised $62.25 million across 10 funding rounds from 19 investors. In May 2026, BioProtect was acquired by Olympus Corporation.
Business overview
BioProtect is a Health Tech & Life Sciences company specializing in medical devices and medical treatment & therapeutics. The company has developed a proprietary technology platform for biodegradable balloons, with its primary application being the BioProtect/ProSpace Balloon System. This system acts as a spacer to protect healthy tissue in patients undergoing radiotherapy for prostate cancer. BioProtect serves the healthcare market, specifically providers, with its products already commercially available in Europe and undergoing clinical studies for FDA approval in the United States.
Strategic signal
In January 2026, a strategic investor signed a memorandum of understanding to acquire BioProtect for approximately $200 million in cash. This acquisition highlights the significant market validation for BioProtect's biodegradable balloon technology, particularly its FDA-approved product for radiation protection during prostate cancer therapy. The deal signals strong investor confidence in the company's innovative approach to improving patient outcomes in radiation oncology and its potential for further product development in tissue protection.
Log in to access full profile ›Company Intelligence Q&A
- What was BioProtect's most significant recent corporate milestone?
- This acquisition followed a memorandum of understanding signed in January 2026, valuing the company at approximately $200 million.
- What is the primary application of BioProtect's technology?
- BioProtect's primary application is the BioProtect/ProSpace Balloon System, which serves as a spacer to protect healthy tissue in patients receiving radiotherapy for prostate cancer.
- When did BioProtect receive FDA approval for its product?
- BioProtect received FDA approval for its product at the end of 2023, specifically for its BioProtect Balloon Implant System for rectal protection during radiation therapy for prostate cancer.
- What was a notable funding round for BioProtect in recent years?
- In September 2023, BioProtect completed a $28 million financing round led by MVM Partners, with participation from Triventures.